These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11086036)

  • 1. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
    Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
    J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
    Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
    J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
    Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
    J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
    Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
    J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
    Rice J; Buchan S; Stevenson FK
    J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
    Nowak AK; Lake RA; Marzo AL; Scott B; Heath WR; Collins EJ; Frelinger JA; Robinson BW
    J Immunol; 2003 May; 170(10):4905-13. PubMed ID: 12734333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion.
    Tanaka Y; Koido S; Xia J; Ohana M; Liu C; Cote GM; Sawyer DB; Calderwood S; Gong J
    J Immunol; 2004 Jun; 172(12):7848-58. PubMed ID: 15187169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of CD4+ T cells precipitates immunopathology in immunodeficient mice infected with a noncytocidal virus.
    Christensen JP; Bartholdy C; Wodarz D; Thomsen AR
    J Immunol; 2001 Mar; 166(5):3384-91. PubMed ID: 11207295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
    Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
    J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
    Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
    J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function.
    Drake DR; Ream RM; Lawrence CW; Braciale TJ
    J Immunol; 2005 Aug; 175(3):1507-15. PubMed ID: 16034088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.